Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-02 09:34 am Sale |
2023-12-31 | 13G | C4 Therapeutics, Inc. CCCC |
Soleus Capital Master Fund, L.P. | 1,835,996 3.700% |
-626,024 (-25.43%) |
Filing History |
| 2024-01-12 4:01 pm Purchase |
2024-01-04 | 13G | C4 Therapeutics, Inc. CCCC |
Betta Investment (Hong Kong) Ltd. | 5,567,928 8.100% |
5,567,928 (New Position) |
Filing History |
| 2024-01-04 4:15 pm Purchase |
2024-01-03 | 13G | C4 Therapeutics, Inc. CCCC |
Point72 Asset Management, L.P. | 2,676,696 5.400% |
2,676,696 (New Position) |
Filing History |
| 2023-12-26 4:30 pm Purchase |
2023-12-14 | 13G | C4 Therapeutics, Inc. CCCC |
RA CAPITAL MANAGEMENT L.P. | 4,878,000 9.900% |
4,878,000 (New Position) |
Filing History |
| 2023-12-22 4:05 pm Purchase |
2023-12-14 | 13G | C4 Therapeutics, Inc. CCCC |
Commodore Capital LP | 3,800,000 7.700% |
3,800,000 (New Position) |
Filing History |
| 2023-11-13 4:55 pm Purchase |
2023-11-01 | 13G | C4 Therapeutics, Inc. CCCC |
Lynx1 Capital Management LP | 3,122,219 6.300% |
3,122,219 (New Position) |
Filing History |
| 2023-07-25 4:40 pm Purchase |
2023-07-19 | 13G | C4 Therapeutics, Inc. CCCC |
Millennium Management LLC | 2,370,504 4.800% |
2,370,504 (New Position) |
Filing History |
| 2023-07-07 4:35 pm Sale |
2023-06-30 | 13G | C4 Therapeutics, Inc. CCCC |
BlackRock Inc. BLK |
2,086,563 4.300% |
-1,534,570 (-42.38%) |
Filing History |
| 2023-06-12 4:13 pm Sale |
2023-05-31 | 13G | C4 Therapeutics, Inc. CCCC |
ArrowMark Colorado Holdings, LLC | 1,493,450 3.040% |
-4,309,421 (-74.26%) |
Filing History |
| 2023-04-14 5:07 pm Purchase |
2023-04-13 | 13G | C4 Therapeutics, Inc. CCCC |
Soleus Capital Master Fund, L.P. | 2,462,020 5.000% |
2,462,020 (New Position) |
Filing History |
| 2023-02-14 5:30 pm Purchase |
2022-12-31 | 13G | C4 Therapeutics, Inc. CCCC |
ArrowMark Colorado Holdings, LLC | 5,802,871 11.850% |
389,143 (+7.19%) |
Filing History |
| 2023-02-14 12:38 pm Sale |
2022-12-31 | 13G | C4 Therapeutics, Inc. CCCC |
T. Rowe Price Associates, Inc. | 2,925,253 6.000% |
-1,159,545 (-28.39%) |
Filing History |
| 2023-02-14 10:08 am Purchase |
2022-12-31 | 13G | C4 Therapeutics, Inc. CCCC |
RTW Investments, LP | 2,819,472 5.800% |
324,507 (+13.01%) |
Filing History |
| 2023-02-08 3:42 pm Purchase |
2023-02-08 | 13G | C4 Therapeutics, Inc. CCCC |
WASATCH ADVISORS LP | 5,775,698 11.800% |
789,626 (+15.84%) |
Filing History |
| 2023-01-31 1:58 pm Purchase |
2022-12-31 | 13G | C4 Therapeutics, Inc. CCCC |
BlackRock Inc. BLK |
3,621,133 7.400% |
215,151 (+6.32%) |
Filing History |
| 2022-06-10 08:44 am Purchase |
2022-05-31 | 13G | C4 Therapeutics, Inc. CCCC |
ArrowMark Colorado Holdings, LLC | 5,413,728 11.090% |
5,413,728 (New Position) |
Filing History |
| 2022-06-06 1:31 pm Purchase |
2022-06-06 | 13G | C4 Therapeutics, Inc. CCCC |
WASATCH ADVISORS LP | 4,986,072 10.200% |
4,986,072 (New Position) |
Filing History |
| 2022-02-14 5:20 pm Sale |
2021-12-31 | 13G | C4 Therapeutics, Inc. CCCC |
PERCEPTIVE ADVISORS LLC | 2,208,913 4.500% |
-949,653 (-30.07%) |
Filing History |
| 2022-02-14 3:11 pm Sale |
2021-12-31 | 13G | C4 Therapeutics, Inc. CCCC |
Cormorant Asset Management LP | 0 0.000% |
-2,490,065 (Position Closed) |
Filing History |
| 2022-02-14 2:34 pm Purchase |
2021-12-31 | 13G | C4 Therapeutics, Inc. CCCC |
T. Rowe Price Associates, Inc. | 4,084,798 8.400% |
4,084,798 (New Position) |
Filing History |